Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
8.10
+0.14 (1.76%)
Jun 2, 2025, 4:00 PM - Market closed
Cybin Employees
Cybin had 50 employees as of March 31, 2024. The number of employees did not change compared to the previous year.
Employees
50
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,444,275
Market Cap
170.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 50 | 0 | - |
| Mar 31, 2023 | 50 | 0 | - |
| Mar 31, 2022 | 50 | 12 | 31.58% |
| Mar 31, 2021 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CYBN News
- 11 days ago - Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 - Business Wire
- 13 days ago - Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Business Wire
- 18 days ago - Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
- 19 days ago - Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - Business Wire
- 25 days ago - Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - Business Wire
- 4 weeks ago - Cybin to Participate at the 28th Annual Milken Institute Global Conference - Business Wire
- 5 weeks ago - Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire
- 6 weeks ago - Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - Business Wire